SNN

SNN

USD

Smith & Nephew SNATS Inc. Common Stock

$28.620-0.390 (-1.344%)

即時價格

Healthcare
醫療器材
英國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$29.010

最高

$29.025

最低

$28.440

交易量

0.13M

公司基本面

市值

12.6B

行業

醫療器材

國家

United Kingdom

交易統計

平均交易量

0.90M

交易所

NYQ

貨幣

USD

52週範圍

最低 $23.69當前 $28.620最高 $31.72

AI分析報告

最後更新: 2025年4月30日
由AI生成數據來源: Yahoo Finance, Bloomberg, SEC

SNN (Smith & Nephew SNATS Inc. Common Stock): What's Happening and What to Watch

Stock Symbol: SNN Generate Date: 2025-04-30 14:43:31

Let's break down what's been going on with Smith & Nephew stock lately and what the tea leaves seem to suggest. We'll look at the latest news, how the price has been moving, and what some prediction models are saying.

Recent News Buzz: A Positive Note

The main piece of news hitting the wires recently (April 29th) is about a new exclusive private label distribution agreement between Smith & Nephew and Nuo Therapeutics.

What's the vibe here? This sounds like a positive development. Essentially, another company (Nuo) is partnering with Smith & Nephew to get its products out there, using SNN's distribution network. For Smith & Nephew, this could mean expanding their product offering without necessarily developing something entirely new from scratch. It suggests SNN is actively working to bring more medical devices to market, which is generally a good sign for a company in this sector. It's a concrete business move that could potentially boost sales down the line.

Price Check: A Recent Pop

Looking at the stock's journey over the past month or so, it's been a bit of a ride. Back in late January/early February, the price was hanging around the $25 mark. It saw a pretty significant jump in late February, climbing into the $28s and even touching $29+ in early March. After that run-up, it pulled back through March, settling mostly in the $27s.

April started with some volatility, including a sharp dip in the first week, but the stock seemed to find its footing and started a gradual climb back up, mostly staying in the mid-to-high $26s.

Now, here's the interesting part: The price data for April 30th shows a notable jump, opening around $28.60 and trading significantly higher than the previous day's close of $26.92. This looks like a strong move up, potentially reacting to the positive news or other market factors. The last recorded price is $28.11.

Comparing this to the AI's prediction for today (0.00% change) is tricky, as the actual price action today seems to have already made a big move up. The AI's prediction might not have fully incorporated the latest trading or news impact. However, the AI does predict a dip after today, suggesting potential downward pressure in the next couple of days (-1.83% tomorrow, -2.75% the day after).

Putting It Together: Outlook & Ideas

So, we have positive news about a distribution deal, a stock price that just saw a significant jump, and an AI model predicting a pullback in the very near term after this jump. What does this picture suggest?

The recent price surge, likely fueled by positive sentiment (perhaps including this news or other factors), shows there's buying interest. However, the AI prediction of a dip, combined with some technical indicators (like the RSI being overbought, as mentioned in the recommendation data), hints that this recent sharp move might be due for a short-term breather or correction.

Apparent Near-Term Leaning: Given the conflicting signals – bullish news and recent price strength versus an overbought condition and AI predicting a dip – the immediate near-term outlook seems cautious. While the underlying news is positive, the stock might see some selling pressure after its recent pop. It leans towards a 'Hold' for those who own it after the jump, or 'Wait and See' for those looking to get in.

Potential Entry Consideration: If you're interested in SNN long-term based on its business, but missed the recent jump, the AI's prediction of a dip could align with a strategy of waiting for a potential pullback. The recommendation data suggested entry points around $26.64 - $26.74 before today's jump. Waiting for the price to potentially settle back towards the high $26s or low $27s might offer a more attractive entry point if the predicted dip occurs. This would be buying on weakness after the initial news reaction.

Potential Exit/Stop-Loss Consideration: For those who bought before the jump, today offered a nice gain. If you're a short-term trader, the AI predicting a dip might be a signal to consider taking some profits. If you're holding longer term, setting a stop-loss is key for managing risk. A potential stop-loss level could be placed below a recent support area or below today's opening price, perhaps around the $27.00 mark, to protect against a significant reversal. The recommendation data suggested a stop-loss at $25.92, which is below the recent April lows and could serve as a more conservative level.

Company Context

Remember, Smith & Nephew is a major player in the medical device world, focusing on areas like joint replacements, sports medicine, and wound care. This distribution agreement with Nuo Therapeutics likely fits into their wound management or potentially sports medicine segments, expanding their offerings in those crucial areas. It's a large, established company ($12B+ market cap) with a global presence. The P/E ratio around 21.8 suggests it's trading at a reasonable multiple compared to some high-growth tech stocks, but it's not necessarily 'cheap' either. The 52-week range ($23.69 - $31.72) shows the stock has seen higher prices in the past year, so the current level is somewhere in the middle of that range, even after the recent jump.


Disclaimer: This analysis is based on the provided data and is for informational purposes only. It is not financial advice. Stock markets are volatile, and prices can move unexpectedly. Always conduct your own thorough research or consult with a qualified financial advisor before making any investment decisions.

相關新聞

Analyst Upgrades

Canaccord Genuity Maintains Hold on Smith & Nephew, Raises Price Target to $28

Canaccord Genuity analyst Caitlin Cronin maintains Smith & Nephew with a Hold and raises the price target from $27 to $28.

查看更多
Canaccord Genuity Maintains Hold on Smith & Nephew, Raises Price Target to $28
GlobeNewswire

Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

HOUSTON, April 29, 2025 (GLOBE NEWSWIRE) -- Nuo Therapeutics, Inc. (OTCQB:AURX) ("Nuo"), a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in

查看更多
Nuo Therapeutics Announces Exclusive Private Label Distribution Agreement with Smith+Nephew

AI預測Beta

AI推薦

看跌

更新於: 2025年5月3日 下午09:37

看跌中立看漲

63.7% 信心度

風險與交易

風險級別3/5
中等風險
適合
保守
交易指南

入場點

$28.46

獲利了結

$29.18

止損

$27.71

關鍵因素

PDI 4.6 在 MDI 3.2 上方,ADX 12.1,表明看漲趨勢
當前價格非常接近支撐位 ($28.52),表明強勁的買入機會
交易量是平均值 (12,222) 的 5.0 倍,表明極強的買入壓力
MACD 0.0061 在信號線 -0.0037 上方,表示看漲交叉

保持更新

設定價格提醒,獲取AI分析更新和即時市場新聞。